TY - JOUR
T1 - COVID-19 vaccination-related delayed adverse events among people with rheumatoid arthritis
T2 - results from the international COVAD survey
AU - COVAD Study Group
AU - Dey, Mrinalini
AU - Doskaliuk, Bohdana
AU - Parodis, Ioannis
AU - Lindblom, Julius
AU - Wincup, Chris
AU - Joshi, Mrudula
AU - Dey, Dzifa
AU - Katchamart, Wanruchada
AU - Kadam, Esha
AU - Sen, Parikshit
AU - Shinjo, Samuel Katsuyuki
AU - Nune, Arvind
AU - Goo, Phonpen Akarawatcharangura
AU - Ziade, Nelly
AU - Chen, Yi Ming
AU - Traboco, Lisa S.
AU - Gutiérrez, Carlos Enrique Toro
AU - Vaidya, Binit
AU - Agarwal, Vikas
AU - Gupta, Latika
AU - Nikiphorou, Elena
AU - Arredondo, Gabriela
AU - Quezada, Ivonne
AU - Calapaqui, Wendy
AU - Idania, Escalante M.
AU - Saenz, Ricardo
AU - Hidalgo, Eduardo Romero
AU - Arrieta, Dina
AU - Sierra-Zorita, Radames
AU - Llerena, Gil Alberto Reyes
AU - Ordóñez, Andrea Bran
AU - Chávez, Nilmo
AU - Obiols, Alejandro Quiñónez
AU - Salinas, Rodrigo García
AU - Pastelin, Carlos Benito Santiago
AU - Alonzo, Hugo
AU - Báez, Jossiell Then
AU - Cristian, Vergara M.
AU - Nunez, Lilith Stange
AU - Ho, Enrique Julio Giraldo
AU - Bautista, Generoso Guerra
AU - Cachafeiro-Vilar, Antonio
AU - Colaman, Nelly
AU - Losanto, Jonathan
AU - Cabriza, Karoll
AU - Fuentes-Silva, Yurilís
AU - Harifi, Ghita
AU - Mohammed, Reem Hamdy A.
AU - Fathi, Hanan Mohammed
AU - Ugarte-Gil, Manuel Francisco
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - This study aimed to assess COVID-19 vaccination-related AEs in patients with rheumatoid arthritis (RA), in the COVID-19 Vaccination in Autoimmune Diseases (COVAD)-2 study. An online international cross-sectional survey captured self-reported data on COVID-19 vaccination-related adverse events (AEs) in people with RA, autoimmune diseases (AIDs; rheumatic [r] and non-rheumatic [nr]) and healthy controls (HCs). The survey was circulated by the COVAD study group, comprising 157 collaborators across 106 countries, from February to June 2022. Delayed AEs among RA were compared with other rAIDs, nrAIDs and HCs using multivariable binary regression. A total of 7203 participants were included (1423 [19.7%] RA, 2620 [36.4%] rAIDs, 426 [5.9%] nrAIDs, 2734 [38%] HCs), with 75% female. Compared to HCs, individuals with RA reported higher overall major AEs [OR 1.3 (1.0–1.7)], and an increased number of several minor AEs. Compared to nrAIDs, people with RA had several increased reported minor AEs including myalgia and joint pain. People with active RA had increased major AEs [OR 1.8 (1.1–3.0)] and hospitalisation [OR 4.1 (1.3 – 13.3)] compared to inactive RA. RA patients without autoimmune comorbidities had significantly fewer major and minor AEs than those with other rAIDs. A decreased incidence of hospitalisation was seen in patients taking methotrexate or TNF inhibitors compared to patients not taking these medications. COVID-19 vaccination is associated with minimal to no risks of delayed AEs in patients with RA compared to HCs, and fewer compared to other rAIDs. Active RA and presence of co-existing rAIDs were associated with an increased risk of delayed AEs.
AB - This study aimed to assess COVID-19 vaccination-related AEs in patients with rheumatoid arthritis (RA), in the COVID-19 Vaccination in Autoimmune Diseases (COVAD)-2 study. An online international cross-sectional survey captured self-reported data on COVID-19 vaccination-related adverse events (AEs) in people with RA, autoimmune diseases (AIDs; rheumatic [r] and non-rheumatic [nr]) and healthy controls (HCs). The survey was circulated by the COVAD study group, comprising 157 collaborators across 106 countries, from February to June 2022. Delayed AEs among RA were compared with other rAIDs, nrAIDs and HCs using multivariable binary regression. A total of 7203 participants were included (1423 [19.7%] RA, 2620 [36.4%] rAIDs, 426 [5.9%] nrAIDs, 2734 [38%] HCs), with 75% female. Compared to HCs, individuals with RA reported higher overall major AEs [OR 1.3 (1.0–1.7)], and an increased number of several minor AEs. Compared to nrAIDs, people with RA had several increased reported minor AEs including myalgia and joint pain. People with active RA had increased major AEs [OR 1.8 (1.1–3.0)] and hospitalisation [OR 4.1 (1.3 – 13.3)] compared to inactive RA. RA patients without autoimmune comorbidities had significantly fewer major and minor AEs than those with other rAIDs. A decreased incidence of hospitalisation was seen in patients taking methotrexate or TNF inhibitors compared to patients not taking these medications. COVID-19 vaccination is associated with minimal to no risks of delayed AEs in patients with RA compared to HCs, and fewer compared to other rAIDs. Active RA and presence of co-existing rAIDs were associated with an increased risk of delayed AEs.
KW - COVID-19
KW - Coronavirus
KW - Rheumatoid arthritis
KW - Survey
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85208802336&partnerID=8YFLogxK
U2 - 10.1007/s00296-024-05742-x
DO - 10.1007/s00296-024-05742-x
M3 - Artículo
C2 - 39503760
AN - SCOPUS:85208802336
SN - 0172-8172
VL - 44
SP - 2853
EP - 2861
JO - Rheumatology International
JF - Rheumatology International
IS - 12
M1 - e001814
ER -